RPL34 Antibody

What applications are RPL34 antibodies validated for?

RPL34 antibodies are primarily validated for Western blot (WB), immunohistochemistry (IHC), immunofluorescence/immunocytochemistry (IF/ICC), and enzyme-linked immunosorbent assay (ELISA) applications. According to validation data, RPL34 antibodies have demonstrated positive Western blot detection in multiple cell lines including HeLa, HepG2, PC-3, and mouse liver tissue. For immunohistochemistry, successful detection has been reported in mouse pancreas tissue, while immunofluorescence applications show positive results in A431 and U-2 OS cell lines .

What are the recommended dilution ratios for different applications?

The optimal dilution ratios vary by application technique:

It's crucial to note that these are general recommendations, and researchers should optimize dilutions for their specific experimental systems. As stated in validation documentation, these reagents should be titrated in each testing system to obtain optimal results .

What species reactivity do commercial RPL34 antibodies demonstrate?

Most commercially available RPL34 antibodies show reactivity against human, mouse, and rat samples. This cross-reactivity is supported by the high sequence conservation of RPL34 across mammalian species. For instance, the immunogen sequence used in some antibodies shows 100% identity between human, mouse, and rat orthologs . This conservation facilitates comparative studies across different model systems .

What are the recommended storage conditions for RPL34 antibodies?

RPL34 antibodies should typically be stored at -20°C for optimal stability. Most commercial preparations are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. These antibodies remain stable for one year after shipment when stored properly. Important to note is that for -20°C storage, aliquoting is often unnecessary, though smaller (20μl) sizes may contain 0.1% BSA as an additional stabilizer .

How should samples be prepared for optimal RPL34 detection in IHC applications?

For immunohistochemical detection of RPL34, antigen retrieval is a critical step. The recommended protocol suggests using TE buffer at pH 9.0 for optimal results. Alternatively, citrate buffer at pH 6.0 can be used for antigen retrieval. This step is particularly important for formalin-fixed, paraffin-embedded tissue samples where protein cross-linking may mask epitopes. Following antigen retrieval, standard blocking and antibody incubation protocols should be followed using the recommended dilution ranges .

What controls should be included in RPL34 antibody experiments?

Effective experimental design for RPL34 studies should include:

• Positive controls: Use tissues or cell lines with validated RPL34 expression such as HeLa cells, HepG2 cells, PC-3 cells, or mouse liver tissue for Western blotting; mouse pancreas tissue for IHC; and A431 cells for immunofluorescence .

• Negative controls: Include samples where the primary antibody is omitted or replaced with non-specific IgG from the same host species (rabbit IgG for most RPL34 antibodies).

• Loading controls: For Western blot applications, include housekeeping proteins (e.g., GAPDH, β-actin) to normalize protein loading.

• Expression validation: Consider validation by orthogonal methods (e.g., qRT-PCR) when studying RPL34 expression levels in experimental models .

How can non-specific binding issues with RPL34 antibodies be resolved?

Non-specific binding can compromise result interpretation in RPL34 detection. To minimize this issue:

• Optimize blocking conditions: Extend blocking time or increase blocking agent concentration (BSA or serum).

• Titrate antibody concentration: Test multiple dilutions within the recommended range (1:500-1:2000 for WB, 1:50-1:500 for IHC and IF) to determine the optimal signal-to-noise ratio .

• Increase washing stringency: Add 0.1-0.3% Tween-20 to washing buffers and increase the number or duration of washes.

• For Western blots: Pre-adsorb the antibody with non-specific proteins or consider using gradient gels to better resolve the 13 kDa RPL34 protein from similarly sized proteins .

What steps should be taken if RPL34 antibody signal is weak or absent?

When confronting weak or absent RPL34 signals:

• Verify sample integrity: Ensure protein degradation hasn't occurred by checking other abundant proteins.

• Optimize protein loading: For Western blots, increase the amount of total protein loaded.

• Enhance sensitivity: For IHC/IF, consider signal amplification methods like tyramide signal amplification or poly-HRP detection systems.

• Adjust antigen retrieval: For IHC applications, compare TE buffer (pH 9.0) versus citrate buffer (pH 6.0) for optimal epitope exposure .

• Verify antibody activity: Test the antibody on positive control samples known to express RPL34, such as HeLa cells or mouse liver tissue .

How can RPL34 detection be optimized in challenging sample types?

Some tissue or cell types may present challenges for RPL34 detection:

• For highly fibrotic tissues: Extended antigen retrieval times may be necessary.

• For tissues with high endogenous peroxidase activity (in IHC): Ensure thorough quenching with H₂O₂ before antibody application.

• For cell lines with low RPL34 expression: Consider enrichment techniques such as immunoprecipitation before Western blot analysis.

• For multi-color immunofluorescence: Carefully select compatible fluorophores and consider sequential rather than simultaneous antibody application to minimize cross-reactivity .

What is the cellular localization and function of RPL34?

RPL34 is a component of the 60S ribosomal subunit, primarily localized in the cytoplasm. It belongs to the L34E family of ribosomal proteins and plays a crucial role in ribosome assembly and protein synthesis. The protein has a calculated molecular weight of 13 kDa, which aligns with its observed molecular weight in experimental systems. As part of the ribosome, RPL34 contributes to the structural integrity of the 60S subunit and participates in the translation process .

The RPL34 gene was originally thought to be located at chromosome 17q21 but has been mapped to chromosome 4q. Multiple transcript variants derived from alternative splicing, alternative transcription initiation sites, and/or alternative polyadenylation exist, though these variants encode the same protein. Like many ribosomal protein genes, RPL34 has multiple processed pseudogenes dispersed throughout the genome .

How is RPL34 expression altered in cancer, and what are the implications?

RPL34 expression varies across cancer types with distinct implications:

• Osteosarcoma: RPL34 is highly expressed in osteosarcoma tissues compared to adjacent normal tissues and normal bone tissues. High expression levels correlate with poor prognosis for osteosarcoma patients. Mechanistically, knockdown of RPL34 in Saos-2 cells inhibits cell proliferation, induces apoptosis, and causes G2/M phase arrest .

• Cervical cancer: Contrary to osteosarcoma, RPL34 appears to act as a tumor suppressor in cervical cancer. RPL34 is downregulated in cervical cancer tissues, and its expression correlates with clinical stage and lymph node metastasis. Functionally, overexpression of RPL34 in Siha cells inhibits proliferation, migration, and invasion capabilities, while silencing RPL34 in Hela cells promotes these processes .

These contrasting roles highlight the context-dependent functions of RPL34 in different cancer types and suggest tissue-specific regulatory mechanisms.

What molecular pathways does RPL34 participate in?

Key molecular interactions of RPL34 include:

• MDM2-P53 pathway: In cervical cancer, RPL34 regulates cellular processes through the MDM2-P53 pathway. Experiments with Actinomycin D (Act D) and MDM2 inhibitor (Nutlin-3) demonstrate that RPL34 affects MDM2 and p53 protein levels without changing their RNA expression, suggesting post-transcriptional regulation .

• Interaction with translation machinery: RPL34 interacts with subunits of eukaryotic translation initiation factor 3 (eIF3) and likely participates in the translational control of growth-promoting proteins .

• Regulation by antisense RNA: RPL34-AS1, an antisense lncRNA located head-to-head with RPL34, positively regulates RPL34 expression. In cervical cancer, RPL34-AS1 suppresses cell proliferation, and this suppression is attenuated by silencing of RPL34, indicating a functional relationship between the antisense RNA and its protein-coding counterpart .

How can researchers investigate the relationship between RPL34 and the MDM2-P53 pathway?

To study RPL34's relationship with the MDM2-P53 pathway:

• Pharmacological approach: Treat cells with Actinomycin D (5 nmol/L) to stabilize p53, then measure changes in RPL34, MDM2, and p53 at both RNA and protein levels using qRT-PCR and Western blot. Additionally, use MDM2 inhibitors like Nutlin-3 (optimally at 30 μmol/L for 6 hours in cervical cancer cell lines) to block MDM2-p53 interaction .

• Genetic manipulation: Overexpress or knock down RPL34 using plasmid transfection or lentivirus-mediated siRNA, then assess effects on MDM2 and p53 expression and downstream cellular processes.

• Protein interaction studies: Perform co-immunoprecipitation assays to determine if RPL34 directly interacts with MDM2 or p53, or affects their interaction.

• Functional rescue experiments: In RPL34-manipulated cells, restore MDM2 or p53 expression to determine if the observed phenotypes are reversible, confirming pathway specificity .

What techniques are recommended for studying RPL34-AS1 regulation of RPL34?

To investigate how the antisense lncRNA RPL34-AS1 regulates RPL34:

• Expression correlation analysis: Perform qRT-PCR to assess correlation between RPL34-AS1 and RPL34 expression in tissue samples, as demonstrated in cervical cancer tissues where a positive correlation was observed .

• Gain and loss of function studies: Overexpress RPL34-AS1 using plasmid transfection (e.g., in Siha cells) or knock it down using lentivirus-mediated approaches (e.g., in Hela cells), then measure changes in RPL34 at both RNA and protein levels .

• Dual manipulation experiments: Combine RPL34-AS1 overexpression with RPL34 knockdown (or vice versa) to assess whether phenotypic effects of manipulating one can be reversed by manipulating the other.

• Mechanistic investigations: Use RNA immunoprecipitation, chromatin isolation by RNA purification, or other techniques to determine if RPL34-AS1 acts through direct interaction with DNA, recruitment of transcription factors, or other epigenetic mechanisms .

How does RPL34 expression correlate with clinical parameters in cancer?

To evaluate RPL34's clinical significance:

• Clinical correlation analysis: In osteosarcoma, high RPL34 expression correlates with poor patient prognosis. In cervical cancer, RPL34 expression correlates with clinical stage and lymph node metastasis .

• Diagnostic value assessment: Using ROC curve analysis for RPL34 in cervical cancer revealed its diagnostic value for clinical staging (optimal threshold 0.397, sensitivity 80.0%, specificity 57.9%) .

• Multivariate analysis: Incorporate RPL34 expression with other clinical parameters in Cox regression models to determine its independent prognostic value.

• Tissue microarray studies: Analyze RPL34 protein expression across larger patient cohorts using tissue microarrays and quantitative immunohistochemistry to establish more robust clinical correlations.

• Meta-analysis: Combine data from multiple studies to evaluate RPL34's consistent role across different cancer types and patient populations .

These methodological approaches provide researchers with a framework for investigating RPL34's complex roles in normal physiology and pathological conditions, particularly in cancer biology.